Rojek Katarzyna, Nickels Eric, Neistadt Barbara, Marquez Rafael, Wickrema Amittha, Artz Andrew, van Besien Koen, Larson Richard A, Lee Ming K, Segal Jeremy P, King Mary-Claire, Walsh Tom, Shimamura Akiko, Keel Sioban B, Churpek Jane E, Godley Lucy A
Section of Hematology/Oncology, Department of Medicine, and The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.
Department of Medicine, Division of Medical Genetics, and Department of Genome Sciences, University of Washington, Seattle, Washington.
Biol Blood Marrow Transplant. 2016 Nov;22(11):2100-2103. doi: 10.1016/j.bbmt.2016.08.002. Epub 2016 Aug 4.
Analysis of the clinical characteristics of hematopoietic stem cell transplant (HSCT) donors has proven beneficial for identifying cases of heritable hematopoietic disorders. This study examines poor peripheral blood hematopoietic stem cell mobilization after granulocyte colony-stimulating factor administration among 328 donors as a potential marker for suspected familial predisposition to myeloid malignancies. Here, we present data comparing the clinical characteristics of poor-mobilizing versus nonpoor-mobilizing donors and the results of panel-based sequencing of hematopoietic genes in poor-mobilizing donors. From this analysis, we identified a novel case of a donor-derived myelodysplastic syndrome in an HSCT recipient that is consistent with clonal evolution of TET2-mutated clonal hematopoiesis of indeterminate potential (CHIP) within the donor. This study demonstrates the potential risk of using hematopoietic stem cells from a donor with CHIP and raises the question of whether there should be increased screening measures to identify such donors.
对造血干细胞移植(HSCT)供者的临床特征进行分析,已证明有助于识别遗传性造血疾病病例。本研究调查了328名供者在给予粒细胞集落刺激因子后外周血造血干细胞动员不佳的情况,将其作为疑似髓系恶性肿瘤家族易感性的潜在标志物。在此,我们展示了比较动员不佳与动员良好的供者临床特征的数据,以及对动员不佳的供者进行造血基因panel测序的结果。通过该分析,我们在一名HSCT受者中发现了一例供者来源的骨髓增生异常综合征,这与供者体内TET2突变的意义未明的克隆性造血(CHIP)的克隆进化一致。本研究证明了使用患有CHIP的供者的造血干细胞存在潜在风险,并提出了是否应加强筛查措施以识别此类供者的问题。